FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a method of production of amorphous ivermectin, which includes the following stages: preparing a solution of ivermectin in at least one solvent; removing the solvent by feeding the solution into a spray dryer and collecting the ivermectin particles; wherein the solvent is an organic solvent selected from ethanol, methanol, methyl ethyl ketone, acetone, 1-butanol, a mixture of organic solvents or water; the concentration of ivermectin in the solution ranges from 2% to 30% by weight of the total mass of the solution.
EFFECT: production of amorphous ivermectin in the form of particles with a granulometric composition from 0.5 microns to 4 microns.
4 cl, 7 dwg, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AMORPHOUS SALT OF MACROCYCLIC HCV INHIBITOR | 2010 |
|
RU2536868C2 |
| METHOD OF PROCESSING PARTICLES OF ACTIVE PHARMACEUTICAL INGREDIENTS | 2011 |
|
RU2597790C2 |
| AMORPHOUS (5-FLUORO-2-METHYL-3-QUINOLIN-2-YLMETHYLINDOL-1-YL)-ACETIC ACID | 2012 |
|
RU2616000C2 |
| FORMS AND COMPOSITION OF PYRIMIDINYL CYCLOPENTANE COMPOUNDS, COMPOSITIONS AND METHODS THEREOF | 2013 |
|
RU2650511C2 |
| COMPOSITION OF THE NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR | 2014 |
|
RU2661399C1 |
| CRTH2 ANTAGONIST PARTICLES | 2008 |
|
RU2468012C2 |
| SOLID DISPERSIONS AND PHARMACEUTICAL COMPOSITIONS INCLUDING SUBSTITUTED INDANE, AND METHODS FOR PRODUCTION AND APPLICATION THEREOF | 2019 |
|
RU2772693C1 |
| ESSENTIALLY CRYSTALLINE MELAGATRAN FORM | 2000 |
|
RU2243973C2 |
| DRY POWDER FORMULATIONS AND METHODS OF TREATING PULMONARY DISEASES | 2010 |
|
RU2577698C2 |
| CRYSTALLINE FORMS OF LTA4H INHIBITOR | 2019 |
|
RU2808992C2 |
